Sharma Kamal, Desai Hardik D, Patoliya Jaimini V, Jadeja Dhigishaba M, Gadhiya Dhruv
Department of Cardiology, U.N. Mehta Institute of cardiology and research center, Affiliated to B.J Medical College, Ahmedabad, 380016 India.
Graduate Medical Education, Gujarat Adani Institute of Medical Sciences, Affiliated to K.S.K.V University, Bhuj, 370001 Gujarat India.
SN Compr Clin Med. 2021;3(1):62-72. doi: 10.1007/s42399-021-00743-4. Epub 2021 Jan 11.
Takotsubo syndrome(TTS) is attributed to catecholamine surge, which is also observed in COVID-19 disease due to the cytokine storm. We performed a systematic literature search using PubMed, Embase, and the Cochrane Central Register of Controlled Trials retrospectively to identify COVID-19-associated TTS case reports and evaluated patient-level demographics, laboratory markers clinical attributes, treatment given, and outcomes. There are 27 cases reported of TTS associated with COVID-19 infection of which 44.5% were male. Reported median age was 57 years (IQR: 39-65) and 62.95 years (IQR: 50.5-73.5) in case series and individual patients' cases in database, respectively. The time interval from the symptom onset to TTS diagnosis was median 6.5 days (IQR: 1.0-8.0) in case series and 6.7 days (IQR: 4-10) in individual patients' database. The median LVEF was 36% (IQR: 35-37) and 38.15%(IQR: 30-42.5%-[male: 40.33% (IQR: 33-44.2)] and female [37.15% (IQR: 30-40)] in case series and individual-patients' database, respectively. Troponin was elevated in all patients except one patient. 77.2% patients of TTS with COVID-19 had an elevated C-reactive protein and/or D-dimer. Twelve out of 22 (54.5%) patients developed cardiac complication such as cardiogenic-shock, atrial fibrillation, acute heart failure, supraventricular tachycardia, and biventricular heart failure. Nineteen out of 26 (73.07%) patients were discharged, and three were hospitalized due to acute respiratory distress syndrome and needed extracorporeal membrane oxygenation or ongoing maternal age. There were 4 (14.8%) mortality. There was no major gender difference observed in development of TTS in COVID-19 unlike COVID-19 per se. Older median age group for TTS in COVID-19 patients irrespective of cardiovascular comorbidities and gender probably reflects age as an independent risk factor. Patients who developed TTS had higher mortality rate especially if they developed cardiogenic shock.
应激性心肌病(TTS)归因于儿茶酚胺激增,在因细胞因子风暴导致的COVID-19疾病中也观察到这种情况。我们使用PubMed、Embase和Cochrane对照试验中央注册库进行了一项系统的文献回顾,以识别与COVID-19相关的TTS病例报告,并评估患者层面的人口统计学特征、实验室指标、临床特征、给予的治疗和结局。报告了27例与COVID-19感染相关的TTS病例,其中44.5%为男性。病例系列和数据库中个体患者病例报告的中位年龄分别为57岁(四分位间距:39 - 65)和62.95岁(四分位间距:50.5 - 73.5)。病例系列中从症状出现到TTS诊断的时间间隔中位值为6.5天(四分位间距:1.0 - 8.0),个体患者数据库中为6.7天(四分位间距:4 - 10)。病例系列和个体患者数据库中左心室射血分数(LVEF)的中位值分别为36%(四分位间距:35 - 37)和38.15%(四分位间距:30 - 42.5% - [男性:40.33%(四分位间距:33 - 44.2)]和女性[37.15%(四分位间距:30 - 40)]。除1例患者外,所有患者肌钙蛋白均升高。77.2%的COVID-19相关TTS患者C反应蛋白和/或D-二聚体升高。22例患者中有12例(54.5%)发生了心脏并发症,如心源性休克、心房颤动、急性心力衰竭、室上性心动过速和双心室心力衰竭。26例患者中有19例(73.07%)出院,3例因急性呼吸窘迫综合征住院,需要体外膜肺氧合或持续治疗。有4例(14.8%)死亡。与COVID-19本身不同,在COVID-19中TTS的发生未观察到明显的性别差异。COVID-19患者中TTS的中位年龄较大,无论有无心血管合并症和性别,这可能反映出年龄是一个独立的危险因素。发生TTS的患者死亡率较高,尤其是发生心源性休克的患者。